非小细胞肺癌老年患者免疫治疗后相继出现免疫性肺炎与免疫性肝炎1例

A Case Report of One Elderly Patient after the Immunotherapy of Non-Small Cell Lung Cancer with Successive Immune Pneumonia and Immune Hepatitis

目的:探讨卡瑞利珠单抗导致非小细胞肺癌患者相继出现免疫性肺炎与免疫性肝炎的防治原则及潜在的机制,保证患者安全用药。方法:回顾1例非小细胞肺癌患者接受卡瑞利珠单抗治疗的病程变化,结合卡瑞利珠单抗相关的临床研究、相关不良反应的诊疗规范,对本案例进行分析。结果:卡瑞利珠单抗导致患者出现免疫性肺炎与免疫性肝炎,期间未予停药,免疫性肺炎给予激素治疗、免疫性肝炎给予对症处理后好转,患者预后良好。结论:使用卡瑞利珠单抗抗肿瘤免疫治疗过程中,需要参考权威指南、结合患者实际情况,持续监测患者的免疫相关不良反应,保证患者用药的安全性及有效性。

Objective: To explore the prevention and treatment principle and potential mechanism of immune pneumonia and immune hepatitis in patients with non-small cell lung cancer caused by camrelizumab. Methods: The course of a patient with non-small cell lung cancer who was treated with camrelizumab was reviewed, and the case was analyzed in combination with the clinical studies related to camrelizumab and the standard of diagnosis and treatment of related adverse reactions. Results: After treatment with camrelizumab, the patient developed immune pneumonia and immune hepatitis, during that period, the drug was not stopped. Immune pneumonia was treated with hormone and immune hepatitis was treated with symptomatic treatment, and the prognosis was good. Conclusion: In the process of tumor immunotherapy with camrelizumab, it is necessary to refer to authoritative guidelines, combined with the actual situation of patients, and continuously monitor the immune-related adverse reactions of patients to ensure the safety and effectiveness of drug use.